Consequently, it is essential to investigate whether the co-expression of other members of the HER family in the EGFR positive cancers may contribute to resistance, or a poor response to therapy with the anti-EGFR mAbs cetuximab and panitumumab in patients with colorectal cancer [6]. Here, EGFR is linked to colorectal cancer.